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Abstract
Background: Breast cancer ranks first in women, and is the second cause of death in this gender. In addition to
genetics, the environment contributes to the development of the disease, although the factors involved are not
well known. Among the latter is the influence of microorganisms and, therefore, attention is recently being paid to
the mammary microbiota. We hypothesize that the risk of breast cancer could be associated with the composition
and functionality of the mammary/gut microbiota, and that exposure to environmental contaminants (endocrine
disruptors, EDCs) might contribute to alter these microbiota.
Methods: We describe a case-control clinical study that will be performed in women between 25 and 70 years of
age. Cases will be women diagnosed and surgically intervened of breast cancer (stages I and II). Women with
antecedents of cancer or advanced tumor stage (metastasis), or who have received antibiotic treatment within a
period of 3 months prior to recruitment, or any neoadjuvant therapy, will be excluded. Controls will be women
surgically intervened of breast augmentation or reduction. Women with oncological, gynecological or endocrine
history, and those who have received antibiotic treatment within a period of 3 months prior to recruitment will also
be excluded. Blood, urine, breast tissue and stool samples will be collected. Data regarding anthropometric,
sociodemographic, reproductive history, tumor features and dietary habits will be gathered.
Metabolomic studies will be carried out in stool and breast tissue samples. Metagenomic studies will also be
performed in stool and breast tissue samples to ascertain the viral, fungal, bacterial and archaea populations of the
microbiota. Quantitation of estrogens, estrogen metabolites and EDCs in samples of serum, urine and breast tissue
will also be performed.
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Discussion: This is the first time that the contribution of bacteria, archaea, viruses and fungi together with their
alteration by environmental contaminants to the risk of breast cancer will be evaluated in the same study. Results
obtained could contribute to elucidate risk factors, improve the prognosis, as well as to propose novel intervention
studies in this disease.
Trial registration: ClinicalTrials.gov NCT03885648, 03/25/2019. Retrospectively registered.
Keywords: Archaea, Bacteria, Breast cancer, Breast microbiota, Endocrine disruptors, Environmental pollutants,
Fungi, Gut microbiota, Virus
Trial status
The trial is currently in progress. Enrolment of patients
and analysis of data continues.
Background
Humans are colonized by commensal microorganisms,
which form the human microbiota. The community of
microorganisms that exist within the gastrointestinal
(GI) ecosystem is termed gut microbiota [1]. The GI
microbiota is mainly composed by up to 1014 bacteria
and several archaea, eukaryotes and virus [2]. In fact,
humans are thought be in involved in a symbiotic rela-
tionship with the gut microbiota [3]. In human health,
the function of the GI microbiota is to keep a dynamic
equilibrium with the host, playing both local and remote
roles [4] in important physiological processes, particu-
larly inflammation and the immune response [2]. This
interspecies balance is named eubiosis [5]. However, a
“disequilibrium” in the microbiota (referred to as dysbio-
sis) may lead to several human diseases [4].
Given that the gastrointestinal tract is a complex,
open, and integrated ecosystem with the external envir-
onment [5], exposure to external insults (i.e. pesticides
and many other pollutants) may lead to dysbiosis. Fail-
ures of host barriers, defects in the immune system, and
loss of eubiosis have been proposed to explain the po-
tential impact of gut microbiota on carcinogenesis [6].
Moreover, it has been suggested that changes in the
microbiota may even promote the development of
extra-intestinal tumors [4] and be involved in its aggres-
siveness [7]. Recent findings revealing gut microbiota
variations in patients with benign compared with malig-
nant tumors suggest that the microbiome profile could
be associated with cancerous state of the tumor [7].
Breast cancer ranks first and is the second cause of
death in women [8]. In addition to genetics, environ-
mental factors such as the influence of microorganisms
could have a role in the development and progression of
this disease [9, 10].
Although human breast tissue was previously pre-
sumed to be sterile, high-throughput technologies re-
vealed a microbiome profile that has recently been
characterized [7]. Furthermore, the local breast
microbiota seems to differ in women with and without
breast cancer [10].
Concerning the influence of microbes on breast can-
cer, some studies have focused on viruses. Up to 50% of
breast tumors are Epstein-Barr positive [11], and human
papilloma virus also appears to be associated with breast
cancer [12]. In addition, the diversity and composition of
the gut microbiota may affect breast cancer risk through
the modulation of systemic levels of estrogens and in-
flammation [13]. In this sense, alterations of microbes
able to metabolize estrogens and other endogenous hor-
mones lead to an increment in circulating estrogen
levels, which ultimately increase the risk of breast cancer
development [14]. Furthermore, a reduced abundance of
Methylobacterium in breast cancer patients has been
correlated with tumors of greater invasive potential [15].
Moreover, exposure to a wide variety of xenobiotics (i.e.
endocrine disruptors compounds (EDCs), which are
found in routinely used products, lead to an increment
of the risk of breast cancer [9]. Indeed, it has been hy-
pothesized that in utero exposure to EDCs plays a role
in breast cancer in women later in life [16]. Altogether,
this background has drawn the attention of the scientific
community in the mammary microbiome direction, al-
beit studies are still very limited and some of the pub-
lished results are contradictory [17].
The rationale of our work is that the risk of breast
cancer could be associated with the composition and
functionality of the mammary/gut microbiota, and that
exposure to environmental contaminants (i.e. EDCs)
might contribute to alter both the gastrointestinal and
mammary microbiota. Consequently, we aim to decipher
the correlation among i) the composition of both the
mammary and the gut microbiota, ii) the metabolic
pathways in which they are involved, iii) the role of
EDCs exposure to its alteration, and iv) the risk and pro-
gression of breast cancer, which might have broad impli-
cations in the prevention, diagnosis, treatment and
prognosis of this disease.
Methods/design
The study will follow the Declaration of Helsinki (52nd
General Assembly, Edinburgh, Scotland, October 2000)
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and the Spaniard legislation regarding clinical research:
Normas de Buena Práctica Clínica y Ley de Investigación
Biomédica Real Decreto 561/1993 y 033/2004. All data
obtained will be confidential and only the researchers
and participants, upon request, will have access to them.
The study will also follow the data protection legislation
of Spain (Ley Orgánica de Protección de Datos de Car-
ácter Permanente, Ley 15/1999 de 13 de Diciembre de
1999) to guarantee data confidentiality, treatment and
availability for the participants.
Participation in the study is volunteer. Participants will
be informed about the nature of the research and the
usage of biological samples as well as the obtained data.
In addition to verbal information, participants will be
presented and read an informed consent. Permission has
been granted by the Ethics Committee of Andalusia
(Comité de Ética de la Investigación Biomédica de Anda-
lucía, Spain).
Study subjects
Inclusion and exclusion criteria
In this ongoing case-control study, already registered in
ClinicalTrials.gov (Identifier NCT03885648), women’s
age will range 25–70 years. Cases will be defined as
women diagnosed and surgically intervened of incident
breast cancer, stages I and II. Controls will be women
surgically intervened of breast augmentation or reduc-
tion. Women with antecedents of cancer or advanced
tumor stage (metastasis), or who have received antibiotic
treatment within a period of 3 months prior to recruit-
ment, or any neoadjuvant therapy, will be excluded of
the study. Women with oncological, gynecological or
endocrine antecedents and those who have received
antibiotic treatment within a period of 3 months prior to
recruitment will be also excluded. Controls will be
matched to cases by age (± 2 years), category of body
mass index and hospital of recruitment.
Sample size
Sample size has been calculated taking into consider-
ation the incidence of breast cancer in Spain, the female
population of Andalusia and the formula described by
Aguilar-Barojas (2005) [18]. Because of that, the number
of breast cancer cases will include at least 100 women,
matched with 100 control women subjected to breast re-
duction or augmentation. Three hospital centers will
participate in the recruitment: The Unit of Mammary
Pathology, General Surgery Service, University Hospital
of Jaén, Spain; the Unit of Mammary Pathology, General
Surgery Service, University Hospital Campus de la Salud,
Granada, Spain; and Ana Moreno Clinic (Granada,
Spain).
Biological samples
Blood, breast tissue, stool and urine samples from cases
and controls will be collected. Cases women will be en-
rolled on the same day of the diagnosis. They will be in-
formed about the goals and procedures of the study and
their participation will be requested, and those who
accept to participate in the study will sign the informed
consent. They will be supplied with a kit containing: 1
thermal bag, 1 freezer block, 1 pair of latex gloves, 1 dis-
posable bedpan, 1 spatula, and 2 disposable plastic con-
tainers for urine and stool samples.
The day of the surgery, a blood sample will be taken.
Serum will be separated by centrifugation to carry out a
thorough biochemical analysis and determine estrogens.
Breast tissue samples will be taken during surgery, from
a marginal area 3–5 cm apart from the tumor. For con-
trols, samples will be taken from any available breast tis-
sue during breast reduction or augmentation surgery.
Both feces and urine samples, from healthy and breast
cancer-affected women will be collected the day previous
to mammary surgery.
Breast and intestinal microbiota
Bacteria, archaea, fungi and viruses will be investigated
in feces and breast tissue samples. Samples will be
pre-treated with pathogen lysis tubes L and S (QIAGEN,
Barcelona, Spain). DNA will be extracted with the
QIAamp cador Pathogen Mini kit (QIAGEN, Barcelona,
Spain), following the manufacturer’s directions.
DNA quantification
The DNA concentration of the samples will be evaluated
in a NanoDrop2000c (Thermo Fisher Scientific, Waltham,
MA, USA).
Metagenomic library construction and sequencing
The Nextera XT DNA Library Preparation Kit (Illumina,
San Diego, CA, USA) will be used for metagenomic li-
brary construction. The amplicon tagment mix (ATM)
in Nextera XT, which includes the enzyme used for tag-
mentation, will be diluted 1:10 in nuclease-free water for
library construction using 1 to 100 pg input DNA. Each
20 μL of the tagmentation reaction mixture consists of
10 μL TD buffer, 5 μL of input DNA, and 5 μL of diluted
ATM. PCR cycles for library construction will be 12, 14,
17, and 20 cycles for 1000, 100, 10, and 1 pg DNA, re-
spectively, following the manufacturer’s protocol. The
manufacturer recommends 12 cycles of the PCR reaction
for no less than 1 ng input DNA. Amplified libraries will
be purified using AMPure XP (Agencourt, Brea, CA,
USA). The quality of the purified libraries will be
assessed using an Agilent High Sensitivity DNA Kit on
an Agilent 2100 Bioanalyzer (Santa Clara, CA, USA).
The sequencing libraries will be further quantified using
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the KAPA Library Quantification Kit. Metagenomic li-
braries will be mixed with PhiX Control v3 (Illumina) at
a ratio of 9:1 and sequenced with an Illumina MiSeq Re-
agent Kit v3 (600 cycles).
All samples to be analyzed will be combined in a pool
before starting the massive sequencing. The latter will
be done with the MiSeq apparatus (Illumina).
Data processing for metagenomic libraries
Metagenomic reads will be subjected to adaptor clipping
and quality trimming using Trimmomatic v0.33 [19]. The
first three nucleotides with quality scores less than 20 will
be cut from the 3′ and 5′ read ends. Reads will be proc-
essed using a sliding window method, cutting once the
average quality within the window (4 base) fell below the
threshold (Q20). Reads with a length of fewer than 100
nucleotides will be then removed. Low-complexity reads
will be filtered out using PRINSEQ version 0.20.4 [20].
PCR duplicates will be removed with Picard version 2.8.0
(http://broadinstitute.github.io/picard). The processed
high-quality and clean reads in each library will be used in
subsequent analyses. In the community analysis based on
metagenomic sequences, small subunit (SSU) rRNA gene
sequences will be identified using Metaxa2 software [21].
Taxonomy assignments will be performed based on the
results of a BLAST search against the SILVA123 database
[22], using the MEGAN program [23] with the following
settings: Min Support 1, Min Score 50, Max Expected
1xe− 5, Top Percent 10.0. SSU rRNA gene community
compositions were compared among the metagenomic
libraries.
Functionality of the intestinal and mammary microbiota
Microbiota functionality will be investigated with a
metabolomic study and by evaluating their capacity to
damage the DNA of HeLa cells.
Metabolomic study
All the metabolomic analyses and data processing will be
carried out with methods previously described [24–26].
Sample preparation The samples will be prepared using
the automated MicroLab STARR (Hamilton Company,
Salt Lake City, UT, USA) robot system. For quality con-
trol (QC) purposes, a recovery standard will be added to
100 L of the serum samples before the first step in the
extraction process. The proteins will be precipitated with
methanol by vigorously shaking for 2 min. Next, the
samples will be centrifuged to remove the proteins, dis-
sociate the small molecules bound to the proteins or
trapped in the precipitated protein matrix, and to re-
cover chemically diverse metabolites (Glen Mills Geno-
Grinder 2000, Lebanon, USA). Then, the samples will be
placed on a TurboVapR (Zymark, California, USA) to
remove the organic solvent. For liquid chromatography
(LC) analysis, the samples will be stored overnight in ni-
trogen before preparation. For gas chromatography (GC)
analysis, each sample will be dried overnight under vac-
uum before preparation [24].
Quality controls Several types of control experiments
will be performed in parallel with the experimental sam-
ples. A pooled matrix sample, generated by taking a
small volume of each experimental sample, will serve as
a technical replicate throughout the extracted data set.
Water aliquots will serve as process blanks. Moreover, a
cocktail of QC standards carefully chosen not to inter-
fere with the measurement of endogenous compounds
will be spiked into every analyzed sample. This will allow
instrument performance monitoring and aid in the chro-
matographic alignment. The instrument variability will
be determined by calculating the median relative stand-
ard deviation (RSD) for the standards that will be added
to each sample before injection into the mass spectrom-
eters (MS). The entire process variability will be deter-
mined by calculating the median RSD for all the
endogenous metabolites (i.e., non-instrument standards)
present in 100% of the pooled matrix samples. The ex-
perimental samples will be randomized across the plat-
form run with the QC samples spaced every 5 or 10
injections to verify overall assay performance [24]. The
internal standards will be used to measure the instru-
ment variability and will have a median RSD of 3%. Add-
itionally, the total process variability will be 8%.
Ultra-performance liquid chromatography-tandem
mass spectrometry The liquid chromatography/mass
spectrometry (LC/MS) portion of the platform to be
used will employ a Waters ACQUITY ultra performance
liquid chromatography (UPLC), a Thermo Scientific
Q-Exactive high-resolution/accurate MS interfaced with
a heated electrospray ionization (HESI-II) source, and an
Orbitrap mass analyzer operated at a 35,000 mass reso-
lution. The sample extract will be dried and reconsti-
tuted in acidic or basic LC-compatible solvents, each of
which will contain eight or more injected QC standards
at fixed concentrations to ensure injection and chroma-
tographic consistency. One aliquot will be analyzed
using acidic, positive ion-optimized conditions, and an-
other will be performed using basic, negative ion opti-
mized conditions in two independent injections using
separate dedicated columns (Waters UPLC BEH C18–
2.1 × 100 mm, 1.7 m). The extracts reconstituted in
acidic conditions will be gradient-eluted from a C18 col-
umn using water and methanol containing 0.1% formic
acid. A second aliquot, from the basic extract, will be
similarly eluted from a C18 column using methanol,
water, and 6.5 mM ammonium bicarbonate. A third
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aliquot will be analyzed via negative ionization following
elution from a hydrophilic interaction chromatography
column (Waters UPLC BEH Amide 2.1 × 150 mm, 1.7
m) using a gradient consisting of water and acetonitrile
with 10mM ammonium formate [24].
Gas chromatography-mass spectrometry The samples
destined for analysis by GC-MS will be dried under a
vacuum for a minimum of 18 h before being derivatized
under dried nitrogen with bistrimethylsilyltrifluoroaceta-
mide. The derivatized samples will be separated on a 5%
diphenyl/95% dimethyl polysiloxane fused silica column
(20 m × 0.18 mm id; 0.18 m film thickness) with helium
as the carrier gas and a temperature ramp from 60C to
340C over a 17.5-min period. The samples will be ana-
lyzed on a Thermo-Finnigan Trace DSQ fast-scanning
single-quadrupole MS using electron impact ionization
(EI) operated at unit mass resolving power. The scan
range will be 50–750 m/z [24].
Data extraction and compound identification The
raw data will be extracted, and the peaks will be aligned
and identified. QCs will be processed using specific
hardware and software [25]. The peaks will be quantified
using the area-under-the-curve (AUC) calculation. The
compounds will be identified comparing the data to li-
brary entries of purified standards or recurrent unknown
entities. The biochemical identifications will be based on
three criteria: the retention index (RI) within a narrow
RI window of the proposed identification, an accurate
mass match to the library ±0.005 amu, and the MS/MS
forward and reverse scores between the experimental
data and authentic standards. The MS/MS scores will be
based on a comparison of the ions present in the experi-
mental spectrum with the ions present in the library
spectrum. Although there may be similarities between
these molecules based on one of these factors, the use of
all three data points can be utilized to distinguish and
differentiate the biochemicals with precision.
Evaluation of DNA damage by determination of
phosphorylated histone 2AX (P-H2AX)
Breast biopsies will be homogenized and seeded onto
specific culture media to isolate bacterial colonies which
later on will be evaluated based on their ability to gener-
ate nicks in the DNA of HeLa cells using the P-H2AX
marker [27]. For this purpose, after colony isolation an
under both aerobic and anaerobic conditions, bacterial
species will be identified by PCR amplification of 16S
rRNA gene. Then bacterial candidates will be used to in-
fect HeLa cells in 24 well-dishes for 24 h. Cells will be
fixed and subjected to immunofluorescence using an
anti-phosphorylated histone 2AX (P-H2AX, rabbit
anti-phosphohistone-2AX MAb; Cell Signaling
Technologies, ref. 9718). Fluorescence intensity will be
measured and the percentage of P-H2AX positive cells
will be calculated.
Quantitation of the exposure to EDCs in urine samples
Analysis of non-persistent EDCs will be carried out by dis-
persive liquid–liquid microextraction (DLLME) and
ultra-high performance liquid chromatography with tan-
dem mass spectrometry detection (UHPLC-MS/MS) as
previously described with minor modifications [28, 29].
Briefly, urine samples will be thawed completely at room
temperature, centrifuge at 2600 x g for 10min to sediment
particulate matter and 0.75mL will be taken to carry out
the analysis. In order to determine total EDCs amount
(free plus conjugated) in urine, each sample will be spiked
with 50 μL of enzyme solution (β-glucuronidase/sulfatase)
and incubated at 37 °C for 24 h. The treated urine will be
placed in a 15mL screw-cap glass tube and spiked with
30 μL of the surrogate standard solution (1.25mg/L of
BPA-d16). Urine will be diluted to 10.0mL with 5% NaCl
aqueous solution (w/v) and the pH will be adjusted to 2.0.
Next, 0.75mL of acetone and 0.75mL of trichloro-
methane will be mixed and injected rapidly into the aque-
ous sample with a syringe. After manual shaking,
centrifugation and evaporation of the extract, the residue
will be dissolved with 100 μL of a mixture consisting of
water (0.1% ammonia)/acetonitrile (0.1% ammonia), 70:30
(v/v), and finally 10 μL will be injected in the LC system.
Urinary creatinine concentration (mg/dL) will be deter-
mined using an automated colorimetric determination, in
the same urine samples in which environmental chemical
will be assessed. Because of the relatively constant excre-
tion rate of creatinine into the urine (which makes urinary
creatinine concentration inversely proportional to urine
flow rate), creatinine adjustment is widely used to
normalize analyte concentrations in spot samples for en-
vironmental exposure monitoring [30].
Bisphenols [bisphenol A (BPA), bisphenol S (BPS) and
bisphenol F (BPF)], parabens [(metylparaben (MeP), ethyl-
paraben (EtP) propylparaben (PrP) and butylparaben (BuP)],
benzophenones [(UV filters: benzophenone-1 (BP-1),
benzophenone-3 (BP-3) and 4-hidroxybenzophenone
(4-OH-BP)] will be determined. Final concentrations will be
adjusted for urinary creatinine levels (mg/dl), to account for
both urine dilution and body composition, as previously re-
ported [31, 32].
Quantitation of urinary concentrations of the parent
estrogens and estrogen metabolites
Concentrations of estrone, estradiol and 13 estrogen me-
tabolites [2-hydroxylated estrogen metabolites (2-hydro-
xyestrone, 2-methoxyestrone, 2-hydroxyestradiol,
2-methoxyestradiol, and 2-hydroxyestrone-3-methyl
ether); 4-hydroxylated estrogen metabolites
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(4-hydroxyestrone, 4-methoxyestrone, and
4-methoxyestradiol); and 16-hydroxylated estrogen me-
tabolites (16α-hydroxyestrone, estriol, 17-epiestriol,
16-ketoestradiol, and 16-epiestriol)] will be determined
in fasting spot urine samples, adjusting for urinary cre-
atinine levels (mg/dL). The quantitation of urinary estro-
gens will be assessed by gas chromatography tandem
mass spectrometry using a triple quadrupole analyzer as
previously described with minor modifications [33, 34].
Briefly, one mL of urine with 25 μL of internal standards
solution will be extracted using C18 SPE cartridge (Sep--
Pack C18) previously conditioned with 4mL of metha-
nol and 4mL of water. After loading the urine sample,
the cartridge will be washed with 4 mL of water. The
treated urine will then be evaporated. Three mL of acet-
ate buffer 0.1 M (pH 4.5) and 3 μL of β-glucuronidase
will be added to the treated urine after being evaporated,
and the mixture will be incubated for 3 h at 55 °C. After
cooling to room temperature, pH will be increased to
approximately 9.5. Then, samples will be extracted with
6 mL of tert-butyl methyl ether by shaking in a rocking
mixer and centrifuged. Finally, the organic layer will be
evaporated to dryness under a stream of nitrogen. Two
μL of the derivatized extract will be injected in split
mode into the GC-MS/MS system. All hormone assess-
ments will be carried out simultaneously to reduce intra-
laboratory variation.
Other sources of information and covariables
Participants’ anthropometric, sociodemographic and re-
productive features will be recorded. They will also grant
permission to access their clinical history.
Anthropometric and sociodemographic information
Age, race, weight, height, residence area (rural/urban),
marital status, education, current working activity, social
class, smoking habits (never, current, former), and alco-
hol consumption (never, current, past), will be recorded.
Reproductive history
Age of menarche and menopause status (premenopause,
postmenopause), number of pregnancies, number of sons,
age at the first and last pregnancy, total duration of breast
feeding, use of hormonal contraceptives and/or substitute
hormonal therapy (age at beginning and duration).
Tumor features
Type and hystological grade according to the Inter-
national Classification of Oncological Diseases
(CIE-0-2); tumor stage: clinical and anatomopathogical
TNM (malignant tumor classification); hormone recep-
tors (estrogens and progesterone); HER2, and tumor
markers (pS2, cathepsin D and p53).
Diet
Participants will answer two questionnaires: adherence to
the Mediterranean diet and frequency of food consumption.
Statistical analysis
Relative abundance of the microbes will be expressed as
median ± range. Differences among microbes will be cal-
culated by the U-Mann de Whitney. Intestinal and
mammary microbiota clusters will be calculated by an
analysis of principal components made with the bio-
informatic data. Those data will be normalized between
0 and 1, and the Euclidean distance will be evaluated. A
permutation ANOVA (PERMANOVA) will be carried
out with the PRIMER 7 software. Finally, a tree diagram
will be built for each evaluated group based on the dif-
ferent taxonomic scales.
For metabolomic statistical analysis and data display
purposes, any missing values will be assumed to be
below the limits of detection, and these values will be
imputed with the compound minimum (minimum value
imputation). The data will be tested for variance homo-
geneity, and if there were unequal variances, the data
will be log-transformed. The statistical analysis of the
data will be performed using Array Studio (OmicSoft,
NC, USA) and proprietary software from Metabolon. A
t-test for equality of the means will be carried out be-
tween the intestinal and mammary microbiota and for
each metabolite to determine differences. A p-value 0.05
will be considered statistically significant. A one-way
ANOVA, assuming homogeneity of variance, will be
used to determine whether at least two unknown means
are all equal or at least one pair of means is different. In
case that the variances were unequal, a Welch-ANOVA
will be performed. The false discovery rate (q-value) will
be calculated to take into account the multiple compari-
sons that normally occur in metabolomics-based studies,
thus estimating the reliability of the results. A q-value
0.1 will be considered statistically significant.
Random forest (RF) is a supervised classification tech-
nique based on an ensemble of decision trees [35] with
several advantages. It makes no parametric assumptions,
and variable selection is not needed. It does not overfit,
and it is invariant to transformation. In RF analysis, it is
not necessary to cross-validate or do a separate test set
to obtain an unbiased estimate of the test set error. A
“variable importance” measure will be computed to de-
termine which variables (metabolites) make the largest
contribution to the classification. The mean decrease in
accuracy (MDA) will be used as this metric and will be
determined by randomly permuting a variable, running
the observed values through the trees, and then reasses-
sing the prediction accuracy. If a variable were not sig-
nificant, then this procedure will have little change in
the accuracy of the class prediction (permuting random
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noise will give random noise). By contrast, if a variable is
relevant for the classification, the prediction accuracy
will drop after such a permutation, which will be re-
corded as the MDA. Thus, the RF analysis provides an
“importance” rank ordering for biochemicals [35].
Participants will be grouped into tertiles of urinary
EDC levels based on their distributions among the con-
trols. Odds ratios and 95% confidence intervals (CIs) for
breast cancer comparing the second and third tertiles
with the first tertile will be estimated using logistic re-
gression models. Further, associations of participant
characteristics with urinary EDC levels, estrogens and
estrogen metabolites and fecal microbiome measures
will be evaluated by using general linear models and
testing either for differences across categories or for
trends across categories. Linear regression models will
also be used to evaluate associations of each steroid
measure with measures of the diversity of the fecal
microbiome, abundance and with taxonomic groups at
phylum and family levels, adjusting by covariates.
Discussion
There are 7 studies registered in ClinicalTrials.gov deal-
ing with breast cancer and microbiota, 2 already com-
pleted and 4 currently ongoing. Of the 2 completed
studies, one investigated the antibiotic profilaxis in
oncological surgery of the breast, and the other investi-
gated the relationship between intestinal bacteria and
breast cancer risk. As for the studies in progress, these
are trials investigating various intervention strategies
(probiotics, physical activity, diet), the effects of gut
microbiome on the neoadjuvant chemotherapy-induced
immunosurveillance in triple negative breast cancer, or
the effects of chemotherapy on gut bacteria in newly di-
agnosed breast cancer. Our study is a case-control clin-
ical trial that aims at ascertaining the connection
relating i) the composition of both gut and breast micro-
biota, ii) the functionality of both gut and breast micro-
biota, and iii) the exposure to environmental
contaminants with the risk of developing breast cancer.
To the best of our knowledge, it is the first study under-
taking the simultaneous analysis of the microbiota of the
mammary tissue and the intestine, and also the first at-
tempt to link the microbiome with the EDC load and
the risk of this disease.
The microbiota is affected by either modifiable and
unmodifiable factors such as genetics, stress, diet, phys-
ical activity, lactation, delivery mode, antibiotic treat-
ment, smoking, age, and alcohol consumption, among
others [36]. For this reason, in an attempt to control
some of the modifiable factors, all participants will an-
swer three questionnaires to record their sociodemo-
graphic data, adherence to the Mediterranean diet, and
frequency of food consumption. For the same reason, we
set stringent inclusion and exclusion criteria. Women
participating in the study will be newly diagnosed cases
of breast cancer. Therefore, women with antecedents of
cancer or advanced tumor stage will not take part, nor
those who have received antibiotic treatment 3months
prior to recruitment, or any neoadjuvant therapy. Like-
wise, regarding the controls, women with oncological,
gynecological or endocrine antecedents and those who
have received antibiotic treatment 3 months prior to re-
cruitment will not be included.
The hypothesis of this study is that the risk of breast
cancer could be associated with the composition and
functionality of the mammary and/or intestinal micro-
biota. The hypothesis is supported by preliminary studies
which suggest that the microbial pattern of women with
breast cancer is different than that of healthy women,
not only with regards to bacterial types and relative
abundance, but also with their functionality (metabolic
capacity, ability y to damage DNA, etc.) [27, 37–39]. Ex-
ogenous factors such as the exposure to EDCs might
contribute to this altered pattern [40, 41]. These circum-
stances would attribute to the microbiota the possibility
of acting as an additional environmental risk factor and
a potential prognostic modulator of the disease.
Validation of the hypothesis could translate into new
recommendations and guidelines of clinical practice to
improve prevention and prognosis of breast cancer, alle-
viating the burden of this disease. Likewise, a better
identification of those patients most likely to efficiently
respond to treatment could derive, given the fact that
efficacy of immunotherapy against cancer depends on
patients’ intestinal microbiota [42, 43]. Finally, interven-
tional clinical studies aimed at shifting the mammary/
gut dysbiosis of women affected by breast cancer toward
a composition similar to that of healthy women could be
designed.
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